Hematology/Oncology

Top Story

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
May 30, 2020
Meeting NewsPerspective

Tucatinib combination extends OS in HER2-positive breast cancer with brain metastases

May 30, 2020
Tucatinib plus trastuzumab and capecitabine extended OS among patients with brain metastases from HER2-positive breast cancer, according to findings from a randomized…
Meeting NewsPerspective

Pyrotinib-capecitabine combination improves outcomes in breast cancer subset

May 30, 2020
Pyrotinib plus capecitabine extended PFS compared with lapatinib-capecitabine among certain patients with HER2-positive metastatic breast cancer, according to randomized…
Meeting News

Ramucirumab-gemcitabine combination confers OS benefit in malignant pleural mesothelioma

May 30, 2020
The addition of ramucirumab to gemcitabine significantly improved survival among patients with malignant pleural mesothelioma, according to randomized phase 2 study…
Meeting NewsPerspective

Metronomic capecitabine maintenance extends DFS in triple-negative breast cancer

May 30, 2020
A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to…
More Headlines »
CME

Clinical Advances and Emerging Trends in Melanoma: A Symposium at the Society for Melanoma Research 2019 Congress

This activity is supported by educational grants from Bristol-Myers Squibb; Iovance Biotherapeutics; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

More »
Video
Meeting News

Early steroid use may reduce CAR T-cell treatment-related toxicity in aggressive lymphoma

December 12, 2019
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

Ace the Case: A 48-Year-Old Woman With a Palpable Left Breast Mass

There is no commercial support for this activity.

More »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next